Skip to content
    Forbion logo

    Forbion

    Naarden, NetherlandsFounded 2006
    forbion.comLinkedIn
    Biotech & Life SciencesFood & Agriculture

    Forbion is a leading European life sciences venture capital firm investing in innovative biotech companies across human health and planetary health. The firm manages approximately €5 billion across multiple fund strategies, spanning formation, ventures, and growth stages, with offices in Naarden, Munich, and Boston.

    67% of their portfolio is in Biotech & Life Sciences. Deal activity increased 78% year-over-year (16 deals in the last 12 months). Average disclosed round size is $103.9M (across 60 rounds with reported amounts).

    Find people at Forbion on Goldilocks AI

    Portfolio

    75

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    18

    Team

    Geert-Jan Mulder MD

    Geert-Jan Mulder MD

    Managing Partner

    Martien van Osch MSc

    Martien van Osch MSc

    Managing Partner & CFO

    Sander Slootweg MSc

    Sander Slootweg MSc

    Managing Partner

    Alexander Hoffmann

    Alexander Hoffmann

    General Partner

    Dmitrij Hristodorov PhD

    Dmitrij Hristodorov PhD

    General Partner

    Jasper Bos PhD

    Jasper Bos PhD

    General Partner

    Jon Edwards PhD

    Jon Edwards PhD

    General Partner

    Marco Boorsma PhD

    Marco Boorsma PhD

    General Partner

    Nanna Lüneborg PhD, MBA

    Nanna Lüneborg PhD, MBA

    General Partner

    Robbert van de Griendt MSc

    Robbert van de Griendt MSc

    General Partner IR & Impact

    Rogier Rooswinkel PhD

    Rogier Rooswinkel PhD

    General Partner

    Wouter Joustra MSc

    Wouter Joustra MSc

    General Partner

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    90 investments
    CompanyRoundAmountDate
    PPrecirixSeries B—Aug 2026
    Kynexis logoKynexisSeries A—Aug 2026
    RQ Bio logoRQ BioSeries A$115MJun 2026
    cAMPfield Therapeutics logocAMPfield TherapeuticsSeries A$180MJun 2026
    CellCentric logoCellCentricSeries D$220MMay 2026
    Mestag Therapeutics Limited logoMestag Therapeutics LimitedSeries B$40MMar 2026
    Tropic logoTropicSeries C$105MMar 2026
    Slate Medicines logoSlate MedicinesSeries A$130MFeb 2026
    AAltesa BiosciencesSeries B$75MFeb 2026
    Beacon Therapeutics logoBeacon TherapeuticsSeries C—Jan 2026
    Memento Medicines logoMemento MedicinesSeries A$93MJan 2026
    RRq Biotechnology LtdSeries A$115MJan 2026
    Protego logoProtegoSeries B$130MDec 2025
    Gate Bioscience logoGate BioscienceSeries B$65MNov 2025
    AAVantgarde Bio logoAAVantgarde BioSeries B$141MNov 2025
    Braveheart logoBraveheartSeries A$185MNov 2025
    BBraveheart BioSeries A$185MNov 2025
    Sparrow Pharmaceuticals logoSparrow PharmaceuticalsSeries B$95MSep 2025
    Elevara Medicines logoElevara MedicinesSeries A$70MSep 2025
    MapLight Therapeutics logoMapLight TherapeuticsSeries D$372.5MJul 2025
    Mosanna Therapeutics logoMosanna TherapeuticsSeries A$80MJun 2025
    Eeden logoEedenSeries A—Apr 2025
    Granite Bio logoGranite BioSeries B$70MApr 2025
    Verdiva Bio logoVerdiva BioSeries A$410MJan 2025
    Numab logoNumabSeries C$55MJan 2025
    Page 1 of 4

    Top Co-Investors

    Sofinnova Partners16 shared
    RA Capital Management14 shared
    OrbiMed10 shared
    Atlas Venture9 shared
    Cormorant Asset Management9 shared
    Sanofi Ventures8 shared
    BioGeneration Ventures8 shared
    Omega Funds8 shared
    Novo Capital8 shared
    Ysios Capital7 shared
    Perceptive Advisors6 shared
    Novo Holdings A/S6 shared
    Frazier Life Sciences5 shared
    EQT Life Sciences5 shared
    Gilde Healthcare5 shared
    Polaris Partners5 shared
    Fountain Healthcare Partners5 shared
    Venrock Healthcare Capital Partners5 shared
    Redmile Group5 shared
    Jeito Capital4 shared

    Last updated: 7 September 2026